Literature DB >> 7086446

CSF and plasma GABA levels in Parkinson's disease.

R J Abbott, I F Pye, S R Nahorski.   

Abstract

CSF gamma-aminobutyric acid (GABA) levels were reduced in patients with idiopathic Parkinson's disease when compared with age matched controls, but the difference was not significant. However, when the Parkinsonian patients were subdivided, CSF GABA levels were lower in the levodopa treated group than in the untreated group and the controls. There was no difference in plasma GABA levels between Parkinsonian patients and controls.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7086446      PMCID： PMC491347          DOI： 10.1136/jnnp.45.3.253

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  8 in total

1.  Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid [3H]GABA binding in the human brain: alterations in Parkinson's disease.

Authors:  K G Iloyd; L Shemen; O Hornykiewicz
Journal:  Brain Res       Date:  1977-05-27       Impact factor: 3.252

2.  Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders.

Authors:  J P Lakke; A W Teelken
Journal:  Neurology       Date:  1976-05       Impact factor: 9.910

3.  Sodium valproate in the treatment of levodopa-induced dyskinesia.

Authors:  P A Price; J D Parkes; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

4.  Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers.

Authors:  M Yoshida; W Precht
Journal:  Brain Res       Date:  1971-09-10       Impact factor: 3.252

5.  The relationship between GABA concentrations in brain and cerebrospinal fluid.

Authors:  P Böhlen; S Huot; M G Palfreyman
Journal:  Brain Res       Date:  1979-05-11       Impact factor: 3.252

6.  Glutamic acid decarboxylase in Parkinson's disease and epilepsy.

Authors:  P L McGeer; E G McGeer; J A Wada
Journal:  Neurology       Date:  1971-10       Impact factor: 9.910

7.  Stability of GABA levels in CSF under various conditions of storage.

Authors:  M H Grossman; T A Hare; N V Manyam; B S Glaeser; J H Wood
Journal:  Brain Res       Date:  1980-01-20       Impact factor: 3.252

8.  Baclofen in Parkinson's disease.

Authors:  A J Lees; K M Shaw; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154
  8 in total
  3 in total

1.  Metabolomic Analysis Provides Insights on Paraquat-Induced Parkinson-Like Symptoms in Drosophila melanogaster.

Authors:  Arvind Kumar Shukla; Ch Ratnasekhar; Prakash Pragya; Hitesh Singh Chaouhan; Devendra Kumar Patel; Debapratim Kar Chowdhuri; Mohana Krishna Reddy Mudiam
Journal:  Mol Neurobiol       Date:  2014-11-27       Impact factor: 5.590

2.  Plasma and cerebrospinal fluid gamma-aminobutyric acid in neurological disorders.

Authors:  D Schmidt; W Löscher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

Review 3.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.